Anvisa approves second generic semaglutide and challenges the pharmaceutical market

Anvisa's approval of the second generic semaglutide medication represents a turning point in competition within the Brazilian pharmaceutical sector, promising to expand access to high-cost treatments that historically weigh on household budgets and impact the IPCA, which accumulated at 4.44% over 12 months with a downward trend compared to 4.64% thirty days earlier. This regulatory advancement directly shakes the margins of major laboratories and opens space for a reconfiguration in the healthcare supply chain, a topic that gains relevance in our recent editorial archive, which has already mapped the need for greater resilience in global supply chains and the pressure for corporate efficiency amidst management challenges in mid-sized companies. To understand the magnitude of this movement, it is essential to observe recent inflation and exchange rate behavior in the country, highlighting the commercial dollar quoted at R$ 5.1625, showing a subtle negative variation of 0.46% compared to 5.186 thirty days ago, which directly affects the import cost of active pharmaceutical ingredients (APIs) from abroad. This exchange rate stability around R$ 5.16 over the past week offers temporary relief for the production costs of domestic pharmaceutical companies, allowing laboratories like Germed to project price reductions that could reach levels at least 35% cheaper compared to reference drugs currently marketed in the Brazilian market. The arrival of new generic competitors in the weight management and diabetes treatment market directly dialogues with the structural perspective of credit and liquidity cycles, where contracting risk appetite and rigorous capital control require companies to seek operational efficiency and sustainable margins without relying exclusively on subsidies or expensive credit. By crossing this scenario with our archive's recent alert on management and professionalization challenges in Brazilian mid-sized companies, it becomes clear that survival in this new competitive environment will depend on a lean cost structure and a highly optimized logistics chain capable of absorbing price pressure without compromising the quality of the final product delivered to the consumer. The risks associated with this transition involve both the scaling capacity of new entrants and the commercial reaction of original patent holders, who may adopt aggressive market share defense strategies through discounts in accredited pharmacy chains. With official 12-month accumulated inflation easing from 4.26% seven days ago to the current 4.44%, the Brazilian consumer gains additional bargaining power, but must remain attentive to the volatility inherent in launch prices, since Germed's product does not yet have an official price table defined with competent regulatory bodies, generating uncertainty about the exact pace of penetration in pharmaceutical retail. Projecting the thirty, ninety, and 180-day time horizon, the Brazilian pharmaceutical market tends to experience a moderate price war, with the gradual entry of new generic brands pressing sector margins downward, while exchange parity around R$ 5.16 will continue to act as an anchor for raw material import costs. In the medium term, decompression is expected.